As today’s caregivers face a rainbow of cultures, issues of race, religion and language can make or break a treatment plan.
The testing of artificial blood has sparked controversy over individual rights.
Television portrays ERs as high-tech places where everyone gets saved. But what’s the real deal?
Pay for performance seems simple: Give doctors financial incentives to improve care. So what’s taking so long?
No-name drugs may be cheaper than brand names, but they have some drawbacks as well.
Debora Spar of the Harvard Business School argues that new medical technology can’t go unregulated forever.
The National Institutes of Health fund much of U.S. medical research. Could budget cuts stem the flow of breakthroughs?
Point: Race is a social construct, not a genetic indicator; Counterpoint: Race correlates highly with genetic variation.
The need for—and dearth of—one precious commodity.
In an environment where doctors are paid by the test, Nortin M. Hadler is convinced that many tests are useless, or worse, harmful.
No Articles Found.
Stay on the frontiers of medicine